New chemoselective peptide heterodimerization and cyclization reactions for the development of novel PET radiopharmaceuticals

用于开发新型 PET 放射性药物的新型化学选择性肽异二聚化和环化反应

• 批准号: 341572-2008
• 负责人: Guérin, Brigitte
• 金额: $ 2.04万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2010
• 资助国家: 加拿大
• 起止时间: 2010-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=458456
• 关键词: New; chemoselective; peptide; heterodimerization; cyclization

Positron emission tomography (PET) is a powerful diagnostic tool for the detection and follow-up of many medical conditions including cancer, heart problems and neurological disorders. The procedure requires the administration of a radiopharmaceutical prior to the PET scan and novel radiopharmaceuticals for the detection of specific medical problems are required to fully exploit this novel diagnostic tool. Peptide hormone receptors expressed in different medical conditions are of particular interest for the development of new, more specific radiopharmaceuticals. The object of this research program is to develop alternative synthetic approaches for the synthesis of a variety of novel peptide derivatives that can subsequently serve as tracers for improved,

正电子发射断层扫描（PET）是一种强大的诊断工具，用于检测和跟踪许多医疗条件，包括癌症，心脏问题和神经系统疾病。该程序要求在PET扫描之前使用放射性药物，并且需要用于检测特定医疗问题的新型放射性药物来充分利用这种新型诊断工具。肽激素受体在不同的医疗条件下表达是特别感兴趣的新的，更具体的放射性药物的发展。本研究计划的目的是开发替代合成方法，用于合成各种新型肽衍生物，这些衍生物随后可作为示踪剂，用于改进；